Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/xmj3t424

A REVIEW ON CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY: A PARADIGM SHIFT IN CANCER IMMUNOTHERAPY

Priyanka .Gadi[1], Dr.Vasudev Purushottam Pai[2] , Girish Adithya A[3], Adarsh. S. Kumar[4] , Saravanagiri A[5], Dr. Salamah Zaheer[6] , Dr. Tanwir Ahamad[7], Lakshya Gayathri Reddy Karri [8], Saniya Naaz[9] , Dr.Varagani Srinivasa Rao[10]

[1] Pharm.D (Doctor of Pharmacy), priyankagadi0628@gmail.com
[2] Pharm.D (Doctor of Pharmacy), vasudevpai995@gmail.com
[3] Pharm.D (Doctor of Pharmacy), girishadithya369@gmail.com
[4] Pharm.D (Doctor of Pharmacy), adarshsk496@gmail.com
[5] Pharm.D (Doctor of Pharmacy), saravanagiriasokan@gmail.com
[6] Pharm.D (Doctor of Pharmacy), Salamahzaheer010@gmail.com
[7] Pharm.D (Doctor of Pharmacy), tanwirahamad758@gmail.com
[8] Pharm.D (Doctor of Pharmacy), lakshyagayathri1801@gmail.com
[9]Pharm.D (Doctor of Pharmacy), naazsaniya680@gmail.com
[10]Pharm.D (Doctor of Pharmacy), Research scholar, varaganisrinivasarao1998@gmail.com

***Corresponding Author:** Priyanka .Gadi
*Pharm.D (Doctor of Pharmacy), priyankagadi0628@gmail.com

ABSTRACT

Chimeric Antigen Receptor (CAR) T-cell therapy has become one of the greatest breakthroughs in cancer immunotherapy, with the ability to cure patients with leukemias and lymphomas, thus changing the entire approach. The procedure made it possible to overcome the drawbacks of an ordinary T-cell response by turning it into an MHC-independent targeted, cytotoxicity with a patient's T-cells that are genetically engineered to recognize and eliminate cancer-specific antigens. This review is about CAR-T cell therapy, describing its biological groundwork, the series of CAR constructs, the making process, action mechanism, and present-day FDA-approved clinical use, showing a vast range of information concerning CAR-T therapy. The investigation into the therapeutic advances in the treatment of leukemia, lymphoma, and multiple myeloma is illustrated along with the difficulties presented in the treatment of solid tumors, which are tumor heterogeneity, the problem of immunosuppressive microenvironments, antigen escape, and limited trafficking. The important toxicities of cytokine release syndrome and neurotoxicity are discussed with a major focus on grading, management strategies, and recent safety-improving developments. Innovations such as dual-target CARs, armored CAR-T cells, allogeneic "off-the-shelf" products, gene-edited CAR-T platforms, and the merging with checkpoint inhibitors point to the rapidly evolving future of this therapy. Finally, CAR-T cell therapy is a game changer in the oncology field, and if continued research expands its application to a greater number of tumors, it will be one of the most personalized, long-lasting, and powerful cancer treatment methods.

Keywords: CAR-T cell therapy; Chimeric Antigen Receptor; cancer immunotherapy; adoptive cell transfer; hematologic malignancies; targeted therapy; cytokine release syndrome; ICANS; tumor microenvironment; engineered T-cells; personalized medicine.

INTRODUCTION

Cancer is still the main cause of sickness and death in many countries around the world, with millions of new cases and deaths each year no matter the progress made in screening and treatment. Conventional treatment modalities, which include surgery, chemotherapy, and radiotherapy, are less effective in raising up some of their limitations such as lack of specificity, systemic toxicity, drug resistance, and failure to thoroughly eliminate minimal residual disease. Targeted therapies and hormonal treatments have better precision, yet tumor heterogeneity, genetic mutations, and development of resistance still limit their effectiveness. The current situation points out the need for more customized and durable solutions to be developed urgently using the technologies that can penetrate the cancer's complexity and adaptability at the same time.[1,2]

The acknowledgment of the immune system's power to identify and remove tumor cells has indirectly facilitated the speedy acceptance of immunotherapy in oncology. Initially, approaches, like the use of cytokines and cancer vaccines, showed just a little bit of success but relied on them to give birth to even more advanced immune-based interventions later on. The launch of immune checkpoint inhibitors made a significant impact on the field of cancer therapy as it not only made the antitumor immune responses active again but also produced long-lasting remissions in many advanced cancers. Nevertheless, a portion of the patients fails to show any response to this kind of treatment, making it imperative to have additional immunotherapeutic strategies. The transformation of the immune system function created conditions where the adoptive cell therapies were born, which are the kind of treatments that take advantage of the natural killing power of your immune system and even amplify it in order to ensure that the cancer is totally eradicated in a very specific and potent way.[3,4]

Therapeutic use of Chimeric Antigen Receptor (CAR) T-cells became the main new method in the area of adoptive cell transfer and eventually cancer immunotherapy. This new approach allowed to overcome all the major mechanisms of immune deception that cancer cells were using. The patients' T-cells would be genetically altered to have the synthetic receptors that can detect the tumors without needing MHC presentation. These changes would let the CAR-T therapy influence and eventually eliminate cancerous cells. The first clinical trials with CAR-T have shown such incredible remission rates in hematologic malignancies that they offer personalized treatment as a very potent option. The use of CAR-T developed by the FDA has promoted and quickened research on the topic of CARs to be designed more optimally, to widen the usage area to solid tumors, and to get the methods used safer and more effective. Thus, CAR-T therapy is still considered an immensely promising approach to changing the landscape of cancer treatment in the near future.[5,6]

IMMUNOBIOLOGY OF T-CELLS AND CANCER RECOGNITION

T-cells are recognized as the principal players of the immune system that react against tumors because they can very specifically recognize and kill cancer cells. When the T-cells are still in the naïve state, they start the process of activation when the T-cell receptors (TCRs) of the T-cells recognize the tumor-associated antigens or the neoantigens that are displayed by the MHC (major histocompatibility complex) molecules present on the surface of the APCs (antigen-presenting cells). Tumor-antigen-specific T-cells become activated only when two signals come through: one from the engagement of the TCR and another from the signaling via costimulatory receptors, e.g., CD28. After the activation, cytotoxic $CD8^+$ T-cells are the first to penetrate the tumor tissues where they secreted perforin, granzyme B, and cytokines that together lead to immediate death of tumor cells. The role of $CD4^+$ T-helper cells is to provide indispensable support by their participation in

the cytokine-based communication (IL-2, IFN-γ) that also enables maintenance and enhancement of $CD8^+$ T-cells. In addition, memory T-cells are the ones who keep the long-lasting surveillance going and block the tumor from coming back by quickly recognizing the tumor antigens after the re-exposure. All the T-cell system forms a very efficient and dynamic immune response that can even spot very small numbers of cancer cells in the very early phases of tumor development.[7]

Mechanisms of T-cell–Mediated Tumor Killing

Cytotoxic T lymphocytes (CTLs) use various methods which have been well-coordinated to kill tumor cells when activated. The main way of killing is through the perforin-granzyme pathway: perforin makes the cell membrane of the tumor cell porous, thus granzyme enzymes can enter and cause the apoptosis by activating the caspases. CTLs also produce Fas ligand (FasL) that sticks to Fash receptors on cancer cells and in this way continues to activate the apoptosis signaling pathway. Moreover, CTLs release pro-inflammatory cytokines like interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α), which strengthen antigen presentation, hinder tumor growth, and bring in other immune cells into the tumor microenvironment. The recognition is very precise—each T-cell produces its TCR for a specific antigen-MHC complex—resulting in accurate targeting of cancer cells and no damage to normal tissues. T-cells by the same token help with immune memory and control of tumors in the long run, thus they remain a potent means of keeping remission in cases of cancer where the T-cells have already been deployed since they are very involved in the whole process.[8]

Tumor Immune Evasion Strategies

T-cell immunity is strong but still there are ways how tumors can avoid getting recognized and destroyed. One of the most employed methods is MHC-I downregulation which makes it impossible for tumor antigens to get presented to the $CD8^+$ T-cells. Tumors also act by signaling T-cell activation is through PD-1 and CTLA-4 binding on T-cells, which, in turn, is via the ligands they produce such as PD-L1 and CTLA-4. In the tumor microenvironment (TME), the recruitment of Tregs, MDSCs, and M2-polarized macrophages that secrete IL-10, TGF-β, and other immune suppressive compounds makes the environment hostile to the immune cells. The cancer cells are also involved in this process as they produce adenosine, indoleamine-2,3-dioxygenase (IDO), and VEGF, which make T-cells ineffective and also restrict their entry into the tumor. The structure of the tumor, which includes abnormal blood vessels, stroma, and a dense extracellular matrix, also poses difficulties to T-cells' movement. All these mechanisms of evasion in concert allow tumors to endure even in the presence of an active immune response.[9]

RATIONALE FOR ENGINEERING CAR T-CELLS

Chimeric antigen receptor (CAR) T-cell therapy was a strategy aimed at natural T-cell immunity and tumor immune escape mechanisms. CARs, in the case of MHC downregulation, which is the primary immune evasion strategy, recognized tumor antigens no matter MHC, hence, bypassed tumor-induced MHC downregulation—one of the main immune evasion strategies. CARs were made up of an extracellular single-chain variable fragment (scFv) that hitched a ride to binding with tumor-specific surface antigens, which in turn, provided the acting force and selectivity—by enabling. Turning the T-cells into CAR T-cells with the help of costimulatory domains (CD28, 4-1BB) leads to an increase in the number of T-cells, their life span, and their presence in the TME. CAR T-cells wait to get their hands on the tumor microenvironment by the ex vivo way of manufacturing that is done to make sure there are enough numbers of T-cells that are highly active and can withstand the suppressive environment. Their proliferative, persistent, and cytotoxic activities make them a “living drug.” The success of CAR T-cells in hematological malignancies has not only confirmed the concept of T-cell genetic reprogramming as a way to avoid immune evasion but also provided a solid reason for the application of such engineering methods to solid tumors and next-generation cellular immunotherapies.[10]

BASIC BIOLOGY OF CAR T-CELL THERAPY

Structure and Components of CAR Molecules

Antigen-Binding Domain (scFv)

The binding domain of the antigen is the part of the CAR molecule which is outside the cell and it is responsible for detecting and attaching to the antigens that are either specific to the tumor or associated with it. Generally, it consists of a single-chain variable fragment (scFv) which comes from the variable regions of the heavy and light chains of a monoclonal antibody, and it is linked together with a flexible peptide linker. This kind of structure offers the advantage of the possibility of very strong and independent MHC antigen recognition, thus giving CAR T-cells a significant benefit compared to the recognition through the native TCR. The scFv is the one that decides the specificity and the therapeutic range of the CAR, hence its selection is of paramount importance for the purposes of off-tumor toxicity reduction and tumor targeting enhancement. Moreover, the stability, affinity, and immunogenicity of scFvs are the main factors that are taken into consideration when designing, since they are the ones that determine the levels of growth, survival, and the occurrence of side effects such as cytokine release syndrome (CRS) being one of them.[11]

Hinge and Transmembrane Region

The hinge (or spacer) is a connector between the scFv and the transmembrane region that grants and perfectly orients the antigen-binding domain to surface antigens at the same time getting access to them. The hinge length and origin—usual being of IgG1, IgG4, CD8α, or CD28—affect antigen binding efficiency, CAR stability, and tumor microenvironment interactions. The transmembrane region secures the CAR to the T-cell membrane and participates in receptor assembly and signal initiation. Typically, transmembrane domains from CD3ζ, CD28, or CD8α are chosen and they not only determine CAR dimerization and expression levels but also decide how long the CAR remains on the cell surface. It is the combination of hinge and transmembrane regions that the CAR function changes as one decides the scFv's closeness and orientation in relation to the tumor cell surface.[12]

Co-stimulatory Domains (CD28, 4-1BB)

Co-stimulatory domains are intra-cellularly positioned within the CAR and are required for maximal T-cell activation, multiplication, and survival. The first-generation CARs did not have these domains and showed only little persistence and anti-tumor activity. The development of co-stimulatory molecules like CD28 and 4-1BB led to the emergence of the second-generation CARs and marked a significant increase in the therapeutic efficacy. CD28-containing CARs lead to rapid T-cell expansion and very high cytotoxicity but may have short persistence. On the other hand, 4-1BB provides slower but continuous activation, which is supportive for long-term persistence, resistance to exhaustion, and memory-like phenotypes. The selection of a co-stimulatory domain affects the antitumor effectiveness, toxicity profiles, metabolic programming, and responses within the tumor microenvironment. A number of third-generation CARs have been designed to combine multiple co-stimulatory elements in such a way that they work together to enhance T-cell performance.[13]

Signaling Domain (CD3ζ)

The signaling domain of the CAR, which is the CD3ζ chain, is the most important part and is taken from the native TCR's CD3 complex. This chain possesses several immunoreceptor tyrosine-based activation motifs (ITAMs), which engage the cascades of downstream signaling once the antigen is presented. The activation of the TCR leads to the execution of the T-cell to which the secretion of cytokines, the release of cytotoxic granules, the proliferation, and the survival belong. The T-cell is already in a state of activation due to this domain and is aided by the co-stimulatory domains to complete the process of full T-cell activation. The arrangement and quantity of ITAMs in CD3ζ can either increase or decrease CAR strength, which is a significant engineering factor for minimizing toxicity and overcoming early T-cell exhaustion. The CD3ζ domain that drives T-cell activation is the foundation of all present CAR constructs.[14]

MECHANISM OF ACTION OF CAR-T CELLS

Antigen Recognition Independent of MHC

One of the most important characteristics of CAR-T cells is that they are able to identify tumor antigens without MHC presentation, while T-cell receptors (TCRs) depend on peptide–MHC complexes. The CAR's scFv or single-chain variable fragment consists of that part of the antibody molecule that specifically binds to the antigen and it is extracellular. This new way of recognition, more like that of antibodies, makes the tumor immune evasion strategies like MHC-I downregulation ineffective, which is the most common method used by malignant cells to escape through cytotoxic T lymphocytes. The ability of CAR-T cells to hit surface antigens without MHC restriction is a huge step forward in treatment options, as it guarantees good recognition even in very immunosuppressive tumors that have weak antigen presentation machinery.[15]

Activation Signals and T-Cell Proliferation

The scFv instigates the target antigen binding and consequently the intracellular signaling cascades that get quickly activated via the CD3ζ chain along with the co-stimulatory domains that are part of the CAR construct. The ITAM activation elicited by CD3ζ triggers T-cell effector functions and at the same time, the stimulation with the co-stimulatory domains like CD28 or 4-1BB leads to T-cell proliferation, metabolic activation, survival, and cytokine production. The action of the dual-signal is T-cell signaling in vivo and thus leads to the clonal expansion of CAR-T cells both in the lab and in the body post-infusion. The expansion of T-cells reaches its maximum within a few days of the encounter with the antigen in the patient’s body, thus, CAR-T cells operate as a “living drug” that can attract their therapeutic effect according to the tumor burden.[16]

Cytotoxic Mechanisms (Granzymes, Perforin, Fas–FasL Pathway)

CAR-T cells are primarily killing tumor cells through the very same mechanisms as their cytotoxic T lymphocyte precursors. The perforin-granzyme route is the most important one, where firstly perforin creates holes in the membrane of the tumor cells, then granzyme B and other serine proteases which are responsible for the caspase-dependent apoptosis infiltrate the cells. Besides that, CAR-T cells are also having the potential to use the Fas-FasL mechanism in which Fas ligand (on T-cells’ surface) and Fas (on tumor cells) formation set off the apoptosis signaling via the extrinsic pathway. Moreover, the upregulation of death-inducing ligands such as TRAIL by CAR-T cells adds on to this apoptotic process. The result of using these cytotoxic mechanisms is a quick and accurate killing of the tumor cells with little or no harm done to the surrounding tissues.[17]

Cytokine Production and Immune Modulation

Activated CAR-T cells are known to release a variety of pro-inflammatory cytokines, including IFN-γ, IL-2, TNF-α, and GM-CSF, which play a crucial role in their antitumor activity. Among the above-mentioned cytokines, IFN-γ and some others act primarily as the signaling molecules to the T-cells, thus increasing their number and lifetime in the tumor area; moreover, they also modify the tumor microenvironment by mounting its aggressiveness through various ways, where, for example, they can increase the antigen presentation, activate macrophages and dendritic cells, and cause the influx of more immune effector T-cells. On the downside, if the production of these cytokines is uncontrolled, then it can be a cause of the systemic inflammatory responses such as cytokine release syndrome (CRS), which is the ultimate adverse effect of CAR-T therapy. Nonetheless, the cytokine-driven immune modulation is still an indispensable part of CAR-T which enhances the therapeutic benefits and makes the coordinated antitumor immunity play a role beyond the direct cytotoxicity.[18]

Long-Term Persistence and Memory T-Cell Formation

The long-term presence of therapeutic agents is very important for their ability to heal and not to relapse in people treated with them. After the cells’ period of extension and tumor complete eradication, a small group of the CAR-T cells goes through an upgrade process and turns into a

memory-like group which consists of central memory and stem cell memory T-cells. Those cell types have prolonged life span, self-renewal, and ability to react instantly when they come across the tumor cells that are still there or have come back. The use of specific co-stimulatory domains—especially 4-1BB—encourages the memory T-cells' formation by giving them support in terms of energy through the mitochondrial biogenesis and oxidative metabolism, and also making them resistant to die over time. The presence of CAR-T cells which are lasting for months to years is like the immune system's eyes in those areas which might be a reason for the long term cure in blood cancers and the "living" nature of their treatment being one of the most important factors.[19]

EVOLUTION OF CAR GENERATIONS

CAR Generation	Key Structural Features	Main Functional Advantage
First Generation	• scFv antigen-binding domain • CD3ζ signaling domain only	Basic T-cell activation; proof of concept for CAR-T design
Second Generation	• scFv • CD3ζ + **one** co-stimulatory domain (CD28 or 4-1BB)	Improved proliferation, survival, and cytotoxicity; enhanced clinical efficacy
Third Generation	• scFv • CD3ζ + **two** co-stimulatory domains (CD28 + 4-1BB)	Synergistic activation, stronger antitumor responses[20]
Fourth Generation (TRUCKs)	• Second-generation CAR backbone • **Inducible cytokine expression** (e.g., IL-12)	Modifies tumor microenvironment; recruits innate immunity; enhances efficacy in solid tumors
Fifth Generation	• Second-generation CAR backbone • **Cytokine receptor domain addition** (e.g., IL-2Rβ + STAT3/5)	More physiological activation; improved persistence; enhanced memory formation; reduced exhaustion[21]

MANUFACTURING AND ADMINISTRATION OF CAR-T CELLS

1. Leukapheresis and T-Cell Collection

The production process starts with leukapheresis, which is the collection of peripheral blood mononuclear cells (PBMCs) from the patient. This process involves blood being passed through an apheresis machine that carefully separates T-cells and returns the other blood components to the patient. The number and the quality of the lymphocytes, especially CD3+ T-cells, influence the success of the subsequent manufacture processes. The leukapheresis product is either directly sent or frozen and transported to a GMP-certified facility where it undergoes further processing.[22]

2. T-Cell Activation and Genetic Modification

The collected T-cells are processed by enriching and activating them when they reach the manufacturing plant. Stimulation systems like anti-CD3/CD28 beads, which simulate antigen presentation, are used for the activation process. The activation process has a dual function of promoting T-cell proliferation and making them amenable to the genetic modification procedure. Transfer of genes is mostly resorted to through the use of viral vectors, one of which would be either a lentiviral or a retroviral vector that actually incorporates the CAR construct into the T-cell DNA. The non-viral vector methods, which include transposon systems and mRNA electroporation, are also available and thus provide options that could possibly lead to less expensive or safer alternatives than the genetically induced viral integration method.[23]

3. Expansion and Quality Control of Modified T-Cells

After transduction with the CAR gene, T-cells expressing the receptor are cultured for a week to two weeks in bioreactors or culture bags. The interleukins IL-2, IL-7, and IL-15 are among the cytokines that keep on supporting the growth and preserving the good functional fitness of the cells. Cells in expansion are constantly monitored for their viability, CAR expression levels, CD4/CD8 ratios, memory phenotypes, and proliferation kinetics. Stringent quality control tests have to be carried out on the product before its release, which include sterility, endotoxin levels, vector copy

number, potency assays, and identity testing. Only the batches that are in compliance with the defined regulatory criteria will be used for clinical trials.[24]

4. Formulation, Cryopreservation, and Transport

After satisfying the quality criteria, CAR T-cells are prepared in infusion media that are compatible with the human body so as not to affect their stability. The majority of the products are cryopreserved with a controlled-rate freezing method and then kept in liquid nitrogen to allow for the maintenance of their viability. The ability to freeze and thaw these cells makes it possible to align the treatment with the patient's condition and the hospital's schedule. Subsequently, the CAR T-cell product is transported back to the healthcare facility through meticulously controlled and validated cryogenic transport systems that ensure the required temperature is maintained throughout the journey.[25]

5. Lymphodepletion Prior to Infusion

Before the CAR-T treatment, patients usually have to take lymphodepleting chemotherapy in order to make the best possible environment for the infused cells. The common combination includes fludarabine together with cyclophosphamide. This procedure cuts down the natural lymphocytes and immunosuppressive cell numbers, thus providing room and growth factors (like IL-7 and IL-15) that are essential for CAR T-cell expansion. Proper lymphodepletion not only allows the engraftment but also the in vivo proliferation and long-term existence of CAR-expressing T-cells, which are all very important for the success of the treatment.[26]

6. CAR-T Cell Infusion and Clinical Monitoring

The last phase of the process consists of the infusion of CAR-T cells through a vein, which is akin to the transfusion of blood products. After the infusion, patients are subjected to strict monitoring for the whole duration of the treatment such as early and late toxicities, which include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections, and cytopenias. Using laboratory markers and imaging, clinicians assess CAR-T cell expansion, persistence, and tumor response. Long-term follow-up—which is often required for 15 years—contributes to the detection of delayed adverse events and evaluation of sustained remission. This ongoing monitoring is absolutely necessary for the reporting of therapeutic durability and patient safety.[27,28]

FDA-APPROVED CAR T-CELL THERAPIES

CAR-T Product (Brand Name)	Target Antigen	Approved Indications	Year of FDA Approval	Key Clinical Outcomes
Tisagenlecleucel (Kymriah)	CD19	• R/R B-cell ALL (≤25 years) • R/R LBCL in adults	**2017**	CR rates: 70–90% in B-ALL; durable remissions in LBCL
Axicabtagene Ciloleucel (Yescarta)	CD19	• R/R large B-cell lymphoma • R/R follicular lymphoma	**2017**	ORR: ~82%; median OS significantly improved vs SOC
Brexucabtagene Autoleucel (Tecartus)	CD19	• R/R mantle cell lymphoma • R/R B-cell ALL (adults)	**2020**	ORR: 87%; CR: 62% in MCL; high durability
Lisocabtagene Maraleucel (Breyanzi)	CD19	• R/R large B-cell lymphoma	**2021**	ORR: 73%; lower CRS and ICANS compared to earlier products
Idecabtagene Vicleucel (Abecma)	BCMA	• R/R multiple myeloma (≥4 prior lines)	**2021**	ORR: 73%; median PFS ~8.8 months

Ciltacabtagene Autoleucel (Carvykti)	BCMA	• R/R multiple myeloma after ≥1 prior line (expanded in 2024)	**2022**	ORR: ~98%; deep and sustained MRD negativity in many patients [29]

THERAPEUTIC APPLICATIONS OF CAR T-CELL THERAPY

The CAR T-cell treatment has been recognized as the one of the most revolutionary breakthroughs in cancer treatment so far, with hematological tumors showing total remission rates never seen before and new tumor types being treated with this method. Its specific approach, the capability to produce long-lasting immune cars, and the immense potential to kill cancerous cells have all contributed to the quick acceptance of this treatment in hospitals. Researchers are working on different aspects of CAR T-cells such as engineering improvements, targeting multiple antigens, and creating a more favorable environment for the tumor that will eventually lead to more applications of this therapy. The major uses of CAR T-cell therapy in both cancer and non-cancer cases are reviewed in the subsequent sections.

1. CAR-T Therapy in B-Cell Acute Lymphoblastic Leukemia (B-ALL)

CAR-T therapy has been able to achieve complete remission rates even in heavily pretreated patients. CARs that target CD19 destroy the malignant blasts with high efficiency and in many instances, offer prolonged remissions. The use of CAR-T therapy for this indication is still the most established and the most clinically transformative application in the field of CAR-T therapy.

2. CAR-T Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)

CAR-T therapy gives a lot of clinical benefit to patients with DLBCL who have relapsed or are refractory and thus, have failed standard chemotherapy and stem cell transplantation. The products that are aimed at CD19 not only increase the overall survival but also give rise to very high objective response rates apart from providing long-term remission in a small group of patients, thus making CAR-T a preferred salvage treatment.[30]

3. CAR-T Therapy in Mantle Cell Lymphoma (MCL)

CAR-T therapy in patients with relapsed or refractory MCL is very effective indeed, as shown by high rates of complete response and long-lasting remission. BTK inhibitor resistant patients are the most significant beneficiaries. The CAR-T cells fight the disease that is aggressive in nature and thus, offer the patients a chance to be completely cured who otherwise would only have limited options to treat them.

4. CAR-T Therapy in Multiple Myeloma (MM)

BCMA-targeted CAR-T therapies have made a huge impact on the treatment of relapsed or refractory multiple myeloma. These treatments not only give fast and deep responses but also result in high negativity of minimal residual disease detection, even among patients who have undergone very extensive treatments. Although the period of effectiveness varies, CAR-T therapy is certainly a major step forward in the direction of enhancing the prognosis of patients with advanced myeloma.[31]

5. CAR-T Therapy in Chronic Lymphocytic Leukemia (CLL)

CAR-T therapy is a good candidate for CLL due to its capacity to reactivate T-cells and thus its combination with ibrutinib is recommended. Response rates are lower compared to other B-cell neoplasms because of the T-cell exhaustion, yet CAR-T cells still manage to achieve considerable remissions in the case of high-risk, relapsed or refractory CLL patients.

6. CAR-T Therapy in Solid Tumors

The obstacles to the use of CAR-T therapy in solid tumors include the difficulties with antigen heterogeneity, dense stroma, and the presence of tumor microenvironments that suppress the

immune system. Nevertheless, the development of armored CARs, chemokine receptor-modified CARs, and dual-targeting CARs all show promising results in preclinical and early clinical settings, thereby widening the scope of this therapy to non-hematologic cancers.[32]

MAJOR ADVERSE EFFECTS OF CAR T-CELL THERAPY

Adverse Effect	Mechanism	Key Clinical Features	Management
Cytokine Release Syndrome (CRS)	Excessive cytokine surge from massive CAR T activation	Fever, hypotension, hypoxia, multi-organ dysfunction	Tocilizumab, corticosteroids, supportive care
ICANS (Neurotoxicity)	Endothelial activation and blood–brain barrier disruption	Confusion, aphasia, seizures, encephalopathy	Corticosteroids, seizure prophylaxis, ICU monitoring
Prolonged Cytopenias	Bone marrow suppression or immune-mediated effects	Neutropenia, anemia, thrombocytopenia	Growth factors, transfusions, infection prophylaxis
B-cell Aplasia	On-target CD19+ B-cell depletion	Hypogammaglobulinemia, recurrent infections	IVIG replacement, infection monitoring
Infections	Immunosuppression + cytopenias + impaired B-cell immunity	Bacterial, viral, fungal infections	Antibiotics/antivirals, prophylaxis, immune support
Secondary Malignancies	Rare vector-related or immune dysregulation effects	New hematologic malignancy	Long-term surveillance, hematologic evaluation[33]

CLINICAL OUTCOMES AND EFFICACY PROFILES

CAR T-cell therapy has made a significant impact in the treatment of blood cancers with its great clinical results, sometimes even pushing the limits of conventional therapy in case of relapse or resistance. In the case of B-cell acute lymphoblastic leukemia (B-ALL), CD19 targeted CAR T-cells have brought about the total remission (CR) rates of more than 70–90%, even in cases of patients who have been previously stem-cell transplanted or gone through multiple chemotherapy regimens. Last but not least, similar results are observed in case of diffuse large B-cell lymphoma (DLBCL) with ORR of 50–80%, where also a large proportion of patients achieve the so-called durable remissions lasting for years, and thus, the great long-term survival benefits are indicated.

For multiple myeloma disease, the therapies targeting BCMA such as idecabtagene vicleucel and ciltacabtagene autoleucel are the CAR T drugs with the best performances so far, which are followed by 73–98% of patients responding positively and getting the status of MRD negativity VERY frequently. These outcomes are astonishing especially with the patient population that has been heavily treated and does not have many alternatives left. And, it is still the case that the CAR T-cell persistence correlates very well with long-term disease control, so it is even more important that T-cells undergo a sort of fitness training and memory formation during production.[34]

The latest information from phase I trials in the field of solid tumors shows good but still not very high outcomes that are getting better. Even though objective responses were much lower than in the case of blood cancers, the developments like dual-antigen targeting, armored CARs, and enhanced tumor infiltration techniques provided some advancements in glioblastoma, sarcomas, and other epithelial cancers treatment. These results point out the slow but certain victory over the tumor microenvironment barriers.

In addition to oncology, the first instances of clinical trials with CAR T-cells in autoimmune diseases suggest that the latter are very potent therapeutic agents. In patients suffering from SLE the T-cell therapy has led to drug-free remission, and reconstitution of the immune system which has opened up an avenue for immunomodulation that is sustainable. All these together illustrate the potentials of CAR T-cell therapy across the indications, therefore, implying the necessity for further research to improve efficacy and lower toxicity.[35]

INNOVATIONS IN CAR T-CELL THERAPY

1. Dual-Target and Multi-Target CARs

Dual-target CARs can detect two different tumor antigens simultaneously thus leading to the reduction of antigen escape along with an increase in the chances of tumor eradication. This tactic clarifies the point of attack and secures the non-return of the tumor especially in the case of mixed cancers like lymphoma and myeloma. Multi-target designs also have some advantages like upscaling the area of tumor coverage, defeating antigen loss, and delivering clinical responses that are not only deeper but also more durable.[36]

2. Armored CAR T-Cells (Cytokine-Secreting CARs)

Armored CAR T-cells are made to be resistant through the secretion of immunomodulatory cytokines such as IL-12, IL-18, or IL-15. By doing so the tumor microenvironment is highly immunosuppressive. The secreted cytokines work in concert with the CARs for T-cell survival, T-cell infiltration, and T-cell cytotoxicity thus making T-cells in solid tumors area a more maturing candidate than the traditional T-cell area where T-cells face functional exhaustion.[37]

3. Universal (Allogeneic) CAR T-Cells

Universal or allogeneic CAR T-cells are the ones that are provided by healthy donors and that are genetically manipulated to remove the possibility of graft-versus-host disease occurring. These products make it possible to have them immediately available, eliminate delays in the manufacturing process and guarantee the same quality. Allogeneic platforms, sustained by CRISPR or TALEN editing, have the power to make CAR therapy a universal treatment.[38]

4. TRUCKs (T Cells Redirected for Universal Cytokine Killing)

TRUCKs are the fourth-generation CAR T-cells which are designed to carry the cytokines to the tumor directly. The by the way of antigen engagement, they secrete IL-12 or similar substances, which is the start of changing the tumor microenvironment, increasing the presentation of the antigen and attracting the innate immune cells. Eventually, they will collaborate with the overall strategy of improving the effectiveness against solid tumors that are resistant to treatment.[39]

5. Logic-Gated and Safety-Switch CARs

Logic-gated CARs use signaling through AND, OR, or NOT to achieve a higher degree of accuracy and to minimize the risk of off-target effects in non-tumor tissues. Safety-switch CARs employ suicide genes that can be turned on and off, thus allowing the controlled killing of CAR T-cells when severe side effects occur. All these developments are prerequisites to ensuring the safety of the therapy and the proper handling of the clinical situation.[40]

6. Next-Generation Gene Editing Technologies

The gene editing methods CRISPR-Cas9, TALENs, and base-editing are among the latest techniques that give researchers the ability to very precisely design CAR constructs and improve T-cells regarding their fitness, survival, and ability to recognize antigens. Also, these methods are used for deleting inhibitory receptors, for the integration of cytokine genes, and for the making of hypoimmunogenic universal CARs, which are main factors in the improvement of efficacy and safety across both hematologic and solid tumors.[41]

7. CAR-NK and CAR-Macrophage Therapies

The CAR-NK and CAR-macrophage systems are strong substitutes for T-cell treatments, offering lower toxicity levels and a lower chance of graft-versus-host disease. CAR-NK cells are capable of very fast cytotoxic responses, while CAR-macrophages are capable of very efficiently entering the solid tumor and improving the presentation of the antigen. The availability of these cell types through CAR-based immunotherapies will be expanded.[42]

LIMITATIONS AND CHALLENGES

1. High Cost and Limited Accessibility

CAR T-cell therapy is still an incredibly costly process because of the personalized manufacturing, advanced setup, and the need for long hospital stays. Certain areas do not have the necessary accredited facilities which results in unequal distribution of the treatment option. The cost involved for both patients and hospitals is one of the major reasons that the therapy is not widely adopted clinically, especially in less developed countries, although the treatment has the potential to be a game changer in blood cancers.

2. Severe and Unpredictable Toxicities

The life-threatening side effects of the therapy, such as the cytokine release syndrome (CRS) and neurotoxicity associated with immune effector cell therapy (ICANS), stand out as the most important issues. The patients may have these side effects but with unpredictable timing and uncertain intensity; hence, the patients will be required to be monitored all the time, provided specialized care and quick intervention. The handling of these issues will not only complicate the treatment, but also escalate the cost and risk which consequently will restrict the application of the therapy to well-resourced hospitals with experienced and skilled staff.

3. Limited Effectiveness in Solid Tumors

The efficacy of CAR T-cells is restricted when it comes to solid tumors due to physical barriers, tumor heterogeneity, and the presence of an immunosuppressive tumor microenvironment. Besides, there is limited antigen availability, which coupled with antigen loss leads to incomplete tumor clearance and the occurrence of relapses. Coming into play are all the factors of poor T-cell infiltration, exhaustion, and tumor-mediated immune evasion as hindrances that make the case for the application of CAR T-cells in solid tumors contrary to the positive outcome displayed in blood cancers.[43]

4. Manufacturing Delays and Technical Failures

The “vein-to-vein” CAR T’s personalized production takes time and several weeks, which may not be convenient for the fast-growing type of cancers. The manufacturing process in the case of an insufficient number of cells or product contamination may take even longer than expected to achieve treatment. These logistical issues directly affect therapy's feasibility, especially when urgent intervention is required to forestall clinical deterioration or disease progression.

5. Regulatory, Ethical, and Long-Term Safety Concerns

The global adoption of CAR T therapy is hindered by the issues of regulation and related infrastructure and variability of clinical expertise. The ethical issues surrounding the therapy involve equitable access and the obligation of the long-term monitoring of patients. Additionally, the uncertainties regarding prolonged CAR T persistence, secondary malignancies and chronic toxicities pose ongoing safety challenges. Continuous surveillance and improved therapeutic designs need to be in place since these challenges highlight the need for the latter.[44]

REGULATORY AND ETHICAL CONSIDERATIONS

1. Regulatory Oversight and Approval Pathways

The complexities, individualized nature, and high-risk profile of CAR T-cell therapies result in their undergoing stringent regulatory scrutiny. Agencies such as the FDA and EMA set the bar very high in terms of quality control, manufacturing practices, and long-term safety studies. The regulatory approvals for these treatments get facilitated by the fast-tracking options, but the differences in the regulatory systems all over the world continue to be the main obstacle for the consistent application and international harmonization of this treatment.

2. Informed Consent and Patient Autonomy

The process of obtaining robust informed consent features prominently in the very complex and potentially dangerous therapies involving CAR T-cells. The patients are obliged to comprehend the whole scenario in terms of risks, benefits, toxic effects, and long-term effects. It is very important

from the ethical point of view to have good communication, to protect the patients' rights, and to promote the practice of shared decision-making, particularly in cases involving vulnerable populations or those who are not able to properly understand advanced cellular therapies.[45]

3. Equity, Accessibility, and Global Disparities

The high costs of treatment, limited availability of certified treatment centers, and requirement of having specific infrastructures are the main factors that contribute to the existence of significant disparities in terms of access to these therapies. The situation where only rich patients can afford to receive life-saving treatments raises serious ethical concerns. To ensure that CAR T-cell therapy becomes globally available without any discrimination, it is necessary to allocate healthcare resources fairly, set up more treatment centers and come up with economical manufacturing processes.

4. Long-Term Safety Surveillance and Data Transparency

The presence of adverse events such as delayed toxicities, T-cell persistence, and secondary malignancies, have made long-term follow-up not only a scientific but also an ethical necessity. The transparent reporting of adverse events, the sharing of data, and the use of real-world evidence systems are all measures that help in making the patients' safety more robust. It is of utmost importance to make patient engagement in long-term monitoring programs happen, even though it is not easy and requires the establishment of supportive frameworks and the provision of constant regulatory guidance.[46]

5. Ethical Issues in Gene Editing and Allogeneic CAR T Products

Technological breakthroughs in gene editing, like CRISPR, provoke the debate of ethics concerning the risk of off-target effects, germline-related issues, and future misuse. The case of allogeneic “off-the-shelf” CAR T products brings in the questions of donor consent, immunogenicity, and long-term safety as challenges. Therefore, in the process of opening innovation, it is necessary to keep up the ethical safeguards that will properly guide the advancing CAR T therapies of the next generation.

FUTURE DIRECTIONS AND RESEARCH OPPORTUNITIES

1. Enhancing CAR T-Cell Efficacy in Solid Tumors

The research for the future is going to focus on the overcoming of solid tumor barriers through the enhancement of the methods of infiltration into the tumor, the alteration of the tumor microenvironment, and the targeting of multiple antigens at the same time. The use of armored CARs, chemokine receptor engineering, and local delivery approaches are some of the strategies that might considerably boost therapeutic responses in solid malignancies that have been resistant to treatment in the past.[47]

2. Development of Universal and Off-the-Shelf CAR T Cells

The allogeneic CAR T-cells from the healthy donors are a promising source for faster treatment, less cost, and more widespread availability. The scientists are working on gene editing techniques that will not only help in preventing graft-versus-host disease and immune rejection but also ensure the consistent quality of the product. The global availability and scalability of universal "off-the-shelf" therapies could be a great breakthrough.

3. Multi-Antigen Targeting to Prevent Tumor Escape

One of the main reasons for relapse is the loss of tumor antigens. The study of dual-target CARs, tandem CARs, and synthetic circuits contributes positively to the detection of tumors and prevention of their escape. The smart CARs that can recognize multiple signals are getting designed in a sophisticated manner to provide durable remission and avoid the emergence of resistance.[48]

4. Improving Safety with Controllable and Logic-Gated CARs

The new approaches that are coming up are centered on the cutting down of serious toxicities like CRS and ICANS. The logic-gated CARs, suicide switches, ON/OFF safety switches, and tunable

dosing systems are granting the precision control of CAR T activity. These new technologies create safer profiles, which in turn, lead to wider clinical application, but with minimized life-threatening complications.

5. CAR T-Cell Therapy Beyond Oncology

Researchers are pushing the limits of CAR T-cell treatments and looking to apply them to autoimmune diseases, viral infections, and fibrosis. The early clinical trials with lupus and refractory autoimmune disorders have shown extremely high hope. The studies, which are aiming at the HIV reservoirs, heart fibrosis, and brain disorders, signify the time of non-cancerous use of CARs.[49]

6. Integrating Artificial Intelligence and Biomarkers in CAR T Development

AI-based modeling, predictive biomarkers, and real-time response monitoring are becoming indispensable tools. Machine learning can enhance the choice of patient, foresee the side effects, and point out antigen discovery. By using the biomarkers to select patients, it is possible to make the treatment more effective, lower the rates of failure, and shorten the manufacturing time.

7. Next-Generation CAR Designs and Synthetic Biology Approaches

With the help of synthetic biology, programmable CARs are made that have excellent pliability, regulated signaling strength, and are responsive to surroundings. Beyond e.g., are TRUCKs, switchable CARs, and cytokine-secreting constructs - which on their own are going to escalate the immune response, push back tumor resistance, and prolong the anti-tumor activity through sustaining it.[50]

CONCLUSION

CAR T-cell therapy has become a game-changer in the field of cancer treatment through its curative possibility for patients who have undergone relapses or refractory hematologic malignancies. Besides, the development of personalized oncology has raised the issue of using and modifying the immune system as a treatment method. The downsides of the therapy are still a lot, though, like the costs which are super high, the serious side effects, and the long delays in production, not to mention the limited efficacy in solid tumors. Meanwhile, new techniques like the targeting of multiple antigens, the use of armored CARs, the development of universal allogeneic products, and the introduction of safety switches that are controllable are all helping to get the cancer therapies to the market faster and also making them more successful in their applications. research that combines synthetic biology, biomarkers, and AI could lead to higher accuracy and lower toxicity in cancer treatment. If the innovations and global collaborations persist, CAR T-cell therapy will soon be safer, cheaper, and applicable to a wider range of diseases.

REFERENCES

1. Nwosu N. Cancer: A Disease of Modern Times? Cureus. 2024 Nov 28;16(11):e74666.
2. Cancer development, progression, and therapy: an epigenetic overview. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M. Int J Mol Sci. 2013;14:21087–21113.
3. Liu D, Che X, Wang X, Ma C, Wu G. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer. Pharmaceuticals (Basel). 2023 Sep 29;16(10):1384.
4. Zhang, M., Liu, C., Tu, J. et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer 24, 136 (2025).
5. Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM, Althobaiti H. Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front Bioeng Biotechnol. 2022 Jun 22;10:797440
6. Sun D, Shi X, Li S, Wang X, Yang X, Wan M. CAR-T cell therapy: A breakthrough in traditional cancer treatment strategies (Review). Mol Med Rep. 2024 Mar;29(3):47
7. Ahmed H, Mahmud AR, Siddiquee MF, Shahriar A, Biswas P, Shimul MEK, Ahmed SZ, Ema TI, Rahman N, Khan MA, Mizan MFR, Emran TB. Role of T cells in cancer immunotherapy: Opportunities and challenges. Cancer Pathog Ther. 2022 Dec 20;1(2):116-126

8. Basu R, Whitlock BM, Husson J, Le Floc'h A, Jin W, Oyler-Yaniv A, Dotiwala F, Giannone G, Hivroz C, Biais N, Lieberman J, Kam LC, Huse M. Cytotoxic T Cells Use Mechanical Force to Potentiate Target Cell Killing. Cell. 2016 Mar 24;165(1):100-110
9. Sari G, Rock KL. Tumor immune evasion through loss of MHC class-I antigen presentation. Curr Opin Immunol. 2023 Aug;83:102329.
10. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020 Mar;17(3):147-167.
11. Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. The antigen-binding moiety in the driver's seat of CARs. Med Res Rev. 2022 Jan;42(1):306-342.
12. Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells. 2020 May 9;9(5):1182
13. Mezősi-Csaplár M, Szöőr Á, Vereb G. CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells. Cancers (Basel). 2023 Jun 7;15(12):3081.
14. Bridgeman JS, Ladell K, Sheard VE, Miners K, Hawkins RE, Price DA, Gilham DE. CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy. Clin Exp Immunol. 2014 Feb;175(2):258-67
15. Chmielewski M, Hombach AA, Abken H. Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol. 2013 Nov 11;4:371
16. Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021 Mar;21(3):145-161.
17. Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019 Mar 14;20(6):1283.
18. Thomas S, Abken H. CAR T cell therapy becomes CHIC: "cytokine help intensified CAR" T cells. Front Immunol. 2023 Jan 9;13:1090959.
19. Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward. Front Immunol. 2020 Apr 22;11:702.
20. Zheng Z, Li S, Liu M, Chen C, Zhang L, Zhou D. Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy. Cancers (Basel). 2023 Jul 3;15(13):3476.
21. Alsaieedi AA, Zaher KA. Tracing the development of CAR-T cell design: from concept to next-generation platforms. Front Immunol. 2025 Jul 17;16:1615212
22. Pessach I, Nagler A. Leukapheresis for CAR-T cell production and therapy. Transfus Apher Sci. 2023 Dec;62(6):103828.
23. Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods. 2003 Apr 1;275(1-2):251-5.
24. Klaver Y, van Steenbergen SC, Sleijfer S, Debets R, Lamers CH. T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients. Front Immunol. 2016 Dec 26;7:648.
25. Brezinger-Dayan K, Itzhaki O, Melnichenko J, Kubi A, Zeltzer LA, Jacoby E, Avigdor A, Shapira Frommer R, Besser MJ. Impact of cryopreservation on CAR T production and clinical response. Front Oncol. 2022 Oct 6;12:1024362
26. Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, Henderson D, Hudecek M, Kremer A, Markman J, Nauerth M, Negre H, Sanges C, Staber PB, Tanzi R, Delgado J, Busch DH, Kuball J, Luu M, Jäger U. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023 Dec 22;14:1303935
27. Fesnak A, Lin C, Siegel DL, Maus MV. CAR-T Cell Therapies From the Transfusion Medicine Perspective. Transfus Med Rev. 2016 Jul;30(3):139-45.

28. Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024 Feb 5;221(2):e20230903.
29. John S, Curran KJ, Hall EM, Keating AK, Baumeister SHC, Nikiforow S, Driscoll T, Moskop A, McNerney KO, Phillips CL, Pulsipher MA, Hsieh EM, Rouce RH, Pasquini MC, Tiwari R, Willert J, Ramos R, Krueger J, Guest E, Grupp SA. Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025 Oct 28;9(20):5249-5262.
30. Goyco Vera D, Waghela H, Nuh M, Pan J, Lulla P. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 2024 Dec 31;20(1):2378543
31. Jangavali, S.S., Hangargekar, P.B., Gangthade, B.U. et al. From lab to lifesaver: the rise of CAR T-cell therapy in oncology. J Egypt Natl Canc Inst 37, 37 (2025).
32. Rojas-Quintero J, Díaz MP, Palmar J, Galan-Freyle NJ, Morillo V, Escalona D, González-Torres HJ, Torres W, Navarro-Quiroz E, Rivera-Porras D, Bermúdez V. Car T Cells in Solid Tumors: Overcoming Obstacles. Int J Mol Sci. 2024 Apr 10;25(8):4170.
33. Adkins S. CAR T-Cell Therapy: Adverse Events and Management. J Adv Pract Oncol. 2019 May-Jun;10(Suppl 3):21-28
34. Wang C, Wang J, Che S, Zhao H. CAR-T cell therapy for hematological malignancies: History, status and promise. Heliyon. 2023 Nov 7;9(11):e21776
35. Koster KL, Colombo I, Hayoz S, Eckhardt K, Rojas Mora A, Hess D, Britschgi C, Haefliger S, Imbimbo M, Bertoni F, Homicsko K, von Moos R, Sessa C, Joerger M, Stathis A. A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK). ESMO Open. 2025 Oct 29;10(11):105876.
36. Simon S, Riddell SR. Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. Blood Cancer Discov. 2020 Aug 3;1(2):130-133
37. Hawkins ER, D'Souza RR, Klampatsa A. Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. Biologics. 2021 Apr 14;15:95-105.
38. Mukhametshin SA, Gilyazova EM, Davletshin DR, Ganeeva IA, Zmievskaya EA, Chasov VV, Petukhov AV, Valiullina AK, Spada S, Bulatov ER. Allogeneic NKG2D CAR-T Cell Therapy: A Promising Approach for Treating Solid Tumors. Biomedicines. 2025 Sep 22;13(9):2314.
39. Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145-54.
40. Nolan-Stevaux O, Smith R. Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol. 2024 Nov 13;15:1490911.
41. Song P, Zhang Q, Xu Z, Shi Y, Jing R, Luo D. CRISPR/Cas-based CAR-T cells: production and application. Biomark Res. 2024 May 31;12(1):54.
42. Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024 Oct;21(10):1089-1108.
43. Luo J, Zhang X. Challenges and innovations in CAR-T cell therapy: a comprehensive analysis. Front Oncol. 2024 Jun 11;14:1399544.
44. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):69
45. Berg P, Schönefeld S, Ruppert-Seipp G, Funk MB. Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment. Transfus Med Hemother. 2022 Nov 29;50(3):218-225
46. Imbach, Kathleen & Patel, Arjun & Levine, Aaron. (2018). Ethical Considerations in the Translation of CAR-T Cell Therapies. Cell and Gene Therapy Insights. 4. 295-307.
47. Bouziana S. Targeting CAR T-Cell Therapy: Molecular Research and Its Future Implication. International Journal of Molecular Sciences. 2025; 26(22):10868

48. Ameen D, Amini-Salehi E, Nayak SS, Ahmed A, Pudimat A, Nasrollahizadeh A, Hosseini K, Hosseini Jebelli SF, Alizadeh Asl A, Nguyen AL. Research trends in CAR-T cell therapy: A comprehensive bibliometric analysis highlighting cardiovascular toxicity and clinical implications. Medicine (Baltimore). 2025 May 16;104(20):e42314.
49. Ho M, Zanwar S, Paludo J. Chimeric antigen receptor T-cell therapy in hematologic malignancies: successes, challenges, and opportunities. Eur J Haematol. 2024;112:197–210
50. Jogalekar MP, Rajendran RL, Khan F, Dmello C, Gangadaran P, Ahn BC. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022;13:925985.